9 Myths About HRT and Cancer Risk That Are Still Harming Women
The number of women who've told me they refused HRT because their doctor said it 'causes breast cancer' — full stop, no nuance — is honestly staggering. The fear is completely understandable, but it was built on a headline, not a finding. Getting to the actual numbers took some digging, and what's there is so much less frightening than what most of us were told.
Learn more about Rose →Myth: The WHI proved HRT causes breast cancer
The 2002 Women's Health Initiative trial tested a single formulation — oral conjugated equine oestrogen combined with medroxyprogesterone acetate — in women with an average age of 63, most of whom were overweight and had never used HRT before. That is not a representative sample of the women HRT is actually prescribed for, and those findings cannot be generalised to all hormone therapy. The trial's own lead researchers have since published papers clarifying that the results were misapplied and that the media interpretation caused measurable harm to public health.
Myth: The increased breast cancer risk from HRT is large and certain
The absolute risk figure that caused so much alarm translates to roughly one additional breast cancer case per 1,000 women per year of combined HRT use — a relative risk increase that is smaller than the risk associated with drinking two units of alcohol a day or being significantly overweight. Many women making this comparison have never been told those numbers sit alongside each other. Risk is only meaningful when it is placed in context, and for most women starting HRT before or just after menopause, the context looks very different from the headlines.
Myth: Oestrogen-only HRT carries the same breast cancer risk as combined HRT
The WHI's oestrogen-only arm — for women who had undergone hysterectomy — actually showed a reduced incidence of breast cancer compared to placebo after several years of follow-up, a finding that received a fraction of the coverage the combined arm attracted. Oestrogen alone and oestrogen combined with a progestogen are physiologically different interventions with meaningfully different risk profiles, and conflating them distorts every conversation women try to have with their doctors. Women with an intact uterus need a progestogen to protect the uterine lining, but the type of progestogen used also matters significantly.
Myth: Body-identical progesterone carries the same risk as synthetic progestogens
The large French E3N cohort study and subsequent research suggest that micronised progesterone — the body-identical form now widely available — appears to carry a significantly lower breast cancer risk than older synthetic progestogens like medroxyprogesterone acetate. The biological mechanism is plausible: synthetic progestogens bind to receptors beyond the progesterone receptor, including androgen and glucocorticoid receptors, in ways that micronised progesterone does not. This distinction is critical and is now reflected in updated guidance from several major menopause societies, though it has not yet filtered into every GP consultation room.
Myth: Transdermal oestrogen carries the same clot risk as oral oestrogen
Oral oestrogen is metabolised through the liver, which affects clotting factor production and raises the risk of venous thromboembolism — a risk that is genuinely present and worth discussing. Transdermal oestrogen delivered via patch, gel, or spray bypasses first-pass liver metabolism entirely, and multiple observational studies show it does not carry the same elevated clot risk. For women who have concerns about clots, or who have risk factors for cardiovascular disease, the route of administration is one of the most clinically important variables in the HRT conversation.
Myth: HRT increases ovarian cancer risk significantly
A widely cited 2015 meta-analysis did find a small increased risk of ovarian cancer with HRT use, amounting to approximately one extra case per 1,000 women using HRT for five years. What rarely accompanied that headline was the fact that the absolute numbers are very small, that the risk appeared to diminish after stopping HRT, and that ovarian cancer remains a relatively rare diagnosis in the general population. For most women, this finding is a legitimate data point to discuss with a clinician rather than a reason to avoid treatment entirely.
Myth: HRT increases the risk of all types of stroke
Oral oestrogen at higher doses is associated with a modest increase in ischaemic stroke risk, but again, route of administration changes the picture substantially. Transdermal oestrogen at standard doses does not appear to increase stroke risk in otherwise healthy women under 60, based on current observational evidence. Age, cardiovascular health at the time of starting HRT, and dose are all variables that matter enormously — and 'HRT causes stroke' as a blanket statement does not accurately represent what the evidence shows.
Myth: Starting HRT after 60 is always too risky
The 'timing hypothesis' — supported by re-analyses of WHI data and the KRONOS Early Estrogen Prevention Study — suggests that women who start HRT close to menopause, typically within ten years or before age 60, may actually gain cardiovascular protection rather than risk. Starting HRT many years after menopause in women who already have established atherosclerosis is a different clinical scenario with a different risk profile. The age cut-off is not a fixed biological law; it is a reflection of how much has changed in the arteries between natural menopause and the point when treatment begins.
Myth: Women with a family history of breast cancer cannot use HRT
A family history of breast cancer is a factor that warrants careful, individualised discussion — not an automatic contraindication. For women carrying BRCA1 or BRCA2 mutations who have undergone risk-reducing surgery, HRT is actively recommended to protect bone density and cardiovascular health, because the surgical menopause itself creates significant health risks that outweigh the hormonal ones. For women with a family history but no confirmed mutation, current guidance from the British Menopause Society and the Menopause Society does not class this as a blanket contraindication, and the quality-of-life and protective benefits of HRT deserve full weight in the conversation.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.